BMC Gastroenterology · 2009 · 94 citations · 15 references
MedicineOncologySurgeryGastrointestinal OncologyGeneral SurgerySurgical OncologyColorectal CancerColorectal SurgeryEndoscopic SurgeryEndoscopic Tumor ResectionGastrointestinal EndoscopyTherapeutic EndoscopyEndoscopic Surgical ResectionEndoscopic Tissue ResectionEndoscopic-assisted ResectionHyaluronic Acid TherapyNeoplastic DiseaseOpen-label TrialsSubmucosal TissueTumor En Bloc Resection
BACKGROUND: Sodium hyaluronate (SH) solution has been used for submucosal injection in endoscopic resection to create a long-lasting submucosal fluid "cushion". Recently, we proved the usefulness and safety of 0.4% SH solution in endoscopic resection for gastric mucosal tumors. To evaluate the usefulness of 0.4% SH as a submucosal injection solution for colorectal endoscopic resection, we conducted an open-label clinical trial on six referral hospitals in Japan. METHODS: A prospective multi-center open-label study was designed. A total of 41 patients with 5-20 mm neoplastic lesions localized in the colorectal mucosa at six referral hospitals in Japan in a single year period from December 2002 to November 2003 were enrolled and underwent endoscopic resection with SH. The usefulness of 0.4% SH was assessed by the en bloc complete resection and the formation and maintenance of mucosal lesion-lifting during endoscopic resection. Safety was evaluated by analyzing adverse events during the study period. RESULTS: The usefulness rate was high (82.5%; 33/40). The following secondary outcome measures were noted: 1) steepness of mucosal lesion-lifting, 75.0% (30/40); 2) intraoperative complications, 10.0% (4/40); 3) time required for mucosal resection, 6.7 min; 4) volume of submucosal injection, 6.8 mL and 5) ease of mucosal resection, 87.5% (35/40). Two adverse events of bleeding potentially related to 0.4% SH were reported. CONCLUSION: Using 0.4% SH solution enabled sufficient lifting of a colorectal intramucosal lesion during endoscopic resection, reducing the need for additional injections and the risk of perforation. Therefore, 0.4% SH may contribute to the reduction of complications and serve as a promising submucosal injection solution due to its potentially superior safety in comparison to normal saline solution.
15
Endoscopic Submucosal Dissection of Early Esophageal Cancer
Tsuneo Oyama, Akihisa Tomori, Kinichi Hotta et al. · Clinical Gastroenterology and Hepatology · 2005 · 608 citations